IceCure Medical (ICCM) showcases ProSense breast cancer study data

Rhea-AI Filing Summary

IceCure Medical Ltd. filed a Form 6-K to furnish a press release dated September 30, 2025 about its ProSense® system’s presence at the European Society of Breast Imaging Congress 2025. The release highlights "unlocking de-escalation of care in breast cancer" and positive results from five independent studies. Most of the press release (excluding its second paragraph) is incorporated by reference into IceCure’s existing Form F-3 and Form S-8 registration statements, meaning that disclosure becomes part of those registration documents going forward unless later superseded.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of: September 2025 (Report No. 6)

Commission File Number: 001-40753

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F             ☐ Form 40-F

CONTENTS

On September 30, 2025, IceCure Medical Ltd. (the “Company”) issued a press release titled “IceCure’s ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented,” a copy of which is furnished as Exhibit 99.1 with this Report of Foreign Private Issuer on Form 6-K. 

The press release attached herewith as Exhibit 99.1 (excluding the second paragraph thereof) is incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-258660, 333-267272 and 333-290046) and Form S-8 (Registration Nos. 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.
99.1		Press release dated September 30, 2025 titled “IceCure’s ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented”

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ICECURE MEDICAL LTD.
Date: September 30, 2025	By:	/s/ Eyal Shamir
		Name:	Eyal Shamir
		Title:	Chief Executive Officer

2

FAQ

What did IceCure Medical (ICCM) disclose in this Form 6-K?

IceCure Medical furnished a press release dated September 30, 2025 discussing its ProSenseae system at the European Society of Breast Imaging Congress 2025, emphasizing de-escalation of care in breast cancer and positive results from five independent studies presented at the event.

How does this 6-K affect IceCure Medicalaeas registration statements?

The press release attached as Exhibit 99.1, excluding its second paragraph, is incorporated by reference into IceCure Medicalas existing Form F-3 and Form S-8 registration statements, becoming part of those offering documents unless later filings or reports supersede that information.

What is highlighted about ProSenseae in IceCure Medicalas press release?

The press release highlights IceCureas ProSenseae system at the European Society of Breast Imaging Congress 2025, focusing on "unlocking de-escalation of care in breast cancer" and reporting positive results from five independent clinical studies presented at that congress.

Which exhibit is attached to IceCure Medicalas September 2025 Form 6-K?

Exhibit 99.1 is attached, consisting of a press release dated September 30, 2025 titled "IceCureas ProSenseae at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented."

Who signed IceCure Medicalas September 30, 2025 Form 6-K?

The Form 6-K was signed on behalf of IceCure Medical Ltd. by Chief Executive Officer Eyal Shamir, confirming that the foreign private issuer caused the report to be submitted under the Securities Exchange Act of 1934 on September 30, 2025.